DOST: 3 more COVID vaccine developers apply for local clinical trials
Image from Kaspersky
MANILA, Philippines — Three more developers of COVID-19 vaccines have applied to conduct clinical trials in the country, the Department of Science and Technology (DOST) said Tuesday.
DOST Undersecretary Rowena Cristina Guevara said that the Task Group on Vaccine Evaluation and Selection has received clinical trial applications from the West China Hospital and Sichuan University, Shenzhen Kangtai Biological Products Co., and Eubiologics Co. Ltd.
“Evaluation of the first two new applications are ongoing, while Eubiologics Co. Ltd is still completing some requirements,” she said in an online media forum.
At present, the Food and Drug Administration (FDA) has already approved three COVID-19 vaccine clinical trials in the country.
The clinical trials of Janssen and Clover Biopharmaceuticals are ongoing. Meanwhile, clinical trials of Sinovac Biotech have yet to start as the FDA awaits the submission of their protocol amendment.
“The DOST is also awaiting the final protocol and list of vaccines from WHO (World Health Organization) so the Solidarity Vaccine Trials may be applied with the Ethics Board and FDA for approval,” Guevara added.
RELATED STORIES:
Belgium’s Janssen starts Covid-19 vaccine clinical trials in PH — DOST
China’s Clover gets FDA clearance to hold COVID-19 vaccine trials in PH
Sinovac gets FDA nod to conduct Covid-19 vaccine trials in PH
JPV
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
